Loading…
Loading…
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results.
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by inflammation and tissue remodeling around and behind the.
Viridian Therapeutics is positioned to transition from late-stage biotech to commercial rare disease player with its TED franchise. Veligrotug's pivotal Phase 3 data in active and chronic TED and an FDA PDUFA date of June 30, 2026, create a near-term commercial entry point. Elegrobart, a subcutaneous follow-on asset, targets market expansion by reducing treatment barriers and is planned for a Q1 2027 BLA submission.
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) announces that diamond drilling has commenced at its Kraken Copper-Nickel-Cobalt Project in Labrador, with the first drill now turning on the initial hole of the Company's fully funded 2026 exploration program. The 2026 program is expected to consist of 50 diamond drill holes designed to systematically infill between widely spaced drill holes completed along the five-kilometre-long Main Zone conductive corridor, where mineralization has been intersected in holes spaced up to one kilometre apart.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for VRDN and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.